Adverse Drug ReactionEIPhvNCT02134587
Educational Intervention in Pharmacovigilance for Hospital Health Professionals
A study testing Multifaceted educational intervention in people with Adverse Drug Reaction, run by Universidade Estadual Paulista Júlio de Mesquita Filho at 1 site in Brazil.
Trial summary
Spontaneous reports by health professionals generate the signals in pharmacovigilance. However, the passive method has limitations and the most important of them are the underreporting and the poor quality of data, hindering the causality assessment of adverse drug events (ADE). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Adverse Drug Reaction
- What is being tested?
- Multifaceted educational intervention
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 203 participants
- Where
- 1 siteBrazil
- Study dates
- Feb 2012to May 2014
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All health professionals (physicians, pharmacists, nurses, auxiliaries of nurses and pharmacists, as well as the multidisciplinary team - social assistants, physiotherapists, audiologists, nutritionists, psychologists, occupational therapists and administrative officers), with employment link at the hospital under study who agree to participate by signing an informed consent form are going to be enrolled.
Who cannot join
- The exclusion criteria meet professionals who will be on sick leave, vacation, those who will not to be registered to carry out the intervention and those who will refuse to answer the questionnaire, despite to having shown interest in participating in the lecture and practical class.
Trial locations and contacts
1 site in 1 country.
Brazil1 site
Hospital Estadual Américo Brasiliense
Américo Brasiliense, São Paulo, 14820-000
About this study
Official title: Implementation of a Hospital Pharmacovigilance Service and Comparison of Algorithms for Adverse Drug Reaction Causality Assessment
Spontaneous reports by health professionals generate the signals in pharmacovigilance. However, the passive method has limitations and the most important of them are the underreporting and the poor quality of data, hindering the causality assessment of adverse drug events (ADE). Therefore, the present study aimed to validate an educational intervention (EI) in pharmacovigilance for hospital health professionals, in order to analyze the impact on the knowledge, skill and attitude in ADE reporting.
Investigators proposed a multifaceted EI which will be developed in four meetings with one hour each. The following activities will be carried out: application of a questionnaire to assess the knowledge, skill and attitude before and after EI; lecture; practical class and education material distribution. The answers of questionnaire are going to be analyzed using content analysis technique. The definitions of World Health Organization and the minimum and desired criteria to fill the ADE form, according to the Pan American Health Organization, are going to be considered gold-standard answers. The statistical test of Wilcoxon-Mann Whitney test for paired samples will be applied, in order to assess the impact of educational intervention on behavior of health professionals (ADE reporting).
Read more
With the present study, the following hypotheses will be tested:
H0= There is no difference between the numbers of ADE reported (behavior/attitudes) before and after the educational intervention.
H1= The numbers of ADE reported before and after the educational intervention are different.
Read the detailed description
A quasi-experimental study with health professionals who acted in a general and public hospital of medium complexity with 104 beds will be performed.
Investigators proposed an educational intervention, with the development of lecture and practical class, application of questionnaire before and after EI and the distribution of educational material. Activities will be developed in four meetings of one hour each one.
In the first meeting, questionnaire will be applied, in order to assess knowledge, skills and attitudes in pharmacovigilance prior to EI. The instrument was elaborated based on previous studies. Second meeting will be comprise a lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material, whose content includes the same issues of presentation. In the third meeting, a practical class will be performed to promote a discussion of a fictitious case of adverse drug reaction (ADR), in order to elucidate the correct fill of ADE form. In the fourth meeting, will be repeated the application of questionnaire, in order to assess the impact of EI. With the aim to verify change behavior of health professionals regarding pharmacovigilance activities, the number of ADE reports made prior and after intervention will be compared.
- Conditions
- Adverse Drug Reaction
- Being tested
- Multifaceted educational intervention
- Keywords
- Health knowledge, attitudes, practices., Adverse drug reaction reporting systems., Pharmacovigilance. Product Surveillance, Postmarketing., Drug-related side effects and adverse reactions.
- Medical subject headings
- Drug-Related Side Effects and Adverse Reactions, Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multifaceted educational interventionOther
- Application of questionnaire of knowledge, attitudes and skills in pharmacovigilance.
- Lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material
- Distribution of educational material
- Practical class to explain the correct fill of adverse drug events form
- Reapplication of questionnaire of knowledge, attitudes and skills in pharmacovigilance.
| Study group | Role | What they receive |
|---|---|---|
| Subjects post educational intervention | Other | Multifaceted educational intervention in pharmacovigilance Receives: Other: Multifaceted educational intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Absolute Number of ADE Reporting (Change Behavior of Health Professionals)
Investigators are going to verify the numbers of adverse drug events reported by health professionals which was made 12 months before educational intervention. A follow up across 12 months post-educational intervention also will be performed, in order to identify the number of adverse drug events reported by health professionals. Prevalence of ADE in both periods will be estimated and compared, in order to asses the impact of the intervention on change behavior of health professionals.
Measured: 12 months
Secondary outcomes (2)
Knowledge (Awareness) Regarding Pharmacovigilance
Knowledge assessment will be performed by content analysis of answers obtained from questionnaire, being assigned scores from zero to ten. Definitions related to pharmacovigilance of World Health Organization will be considered gold-standard answers. Scores below five will be classified as unsatisfactory, among five and 7.5 were considered regular and above 7.6 satisfactory on the knowledge acquisition.The questionnaire will be applied in the first (prior to educational intervention) and fourth (post-educational intervention period) meetings. Data will be compared, in order to assess the impact of educational intervention on knowledge of health professionals.
Measured: Two days
Quality of ADE Reports
Skills evaluation will be carried out according to the perception of the voluntary regarding the relevance´s degree of the information to be filled in ADE form. Therefore, in the first (prior to educational intervention) and fourth (post-educational intervention period) meetings, subjects will be asked to highlight the fields of ADE form, according to unnecessary, necessary or essential information to be reported. Minimal and desirable criteria to be filled in ADE form preconized by Pan-American Health Organization will be considered gold-standard answers. Scores from zero to ten will be assigned, according to gold-standard answers. Data will be compared, in order to estimate the impact of educational intervention on skills to fill ADE form.
Measured: Two days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 May 2014 (estimated)
- Study startFeb 2012
- Primary completionSep 2013
- Study completionMay 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Adverse Drug ReactionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 203 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Fabiana Rossi Varallo, Universidade Estadual Paulista Júlio de Mesquita Filho
- Investigators
- Patricia C Mastroianni, PhD, Study chair, School of Pharmaceutical Sciences of UnespFabiana R Varallo, Master, Principal investigator, School of Pharmaceutical Sciences of Unesp
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02134587
- Sponsor's protocol ID
- E015/10
- Acronym
- EIPhv
- Status last verified
- Jun 2023
- First submitted
- 5 May 2014
- Last updated
- 5 Jun 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Figueiras A, Tato F, Fontainas J, Gestal-Otero JJ. Influence of physicians' attitudes on reporting adverse drug events: a case-control study. Med Care. 1999 Aug;37(8):809-14. doi: 10.1097/00005650-199908000-00010.
PubMed 10448723Herdeiro MT, Figueiras A, Polonia J, Gestal-Otero JJ. Physicians' attitudes and adverse drug reaction reporting : a case-control study in Portugal. Drug Saf. 2005;28(9):825-33. doi: 10.2165/00002018-200528090-00007.
PubMed 16119975Herdeiro MT, Figueiras A, Polonia J, Gestal-Otero JJ. Influence of pharmacists' attitudes on adverse drug reaction reporting : a case-control study in Portugal. Drug Saf. 2006;29(4):331-40. doi: 10.2165/00002018-200629040-00004.
PubMed 16569082Gerritsen R, Faddegon H, Dijkers F, van Grootheest K, van Puijenbroek E. Effectiveness of pharmacovigilance training of general practitioners: a retrospective cohort study in the Netherlands comparing two methods. Drug Saf. 2011 Sep 1;34(9):755-62. doi: 10.2165/11592800-000000000-00000.
PubMed 21830837Pedros C, Vallano A, Cereza G, Mendoza-Aran G, Agusti A, Aguilera C, Danes I, Vidal X, Arnau JM. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Saf. 2009;32(1):77-83. doi: 10.2165/00002018-200932010-00007.
PubMed 19132807Figueiras A, Herdeiro MT, Polonia J, Gestal-Otero JJ. An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. JAMA. 2006 Sep 6;296(9):1086-93. doi: 10.1001/jama.296.9.1086.
PubMed 16954488Herdeiro MT, Ribeiro-Vaz I, Ferreira M, Polonia J, Falcao A, Figueiras A. Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Saf. 2012 Aug 1;35(8):655-65. doi: 10.1007/BF03261962.
PubMed 22788235Herdeiro MT, Polonia J, Gestal-Otero JJ, Figueiras A. Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Saf. 2008;31(4):335-44. doi: 10.2165/00002018-200831040-00007.
PubMed 18366244Ribeiro-Vaz I, Herdeiro MT, Polonia J, Figueiras A. Strategies to increase the sensitivity of pharmacovigilance in Portugal. Rev Saude Publica. 2011 Feb;45(1):129-35. doi: 10.1590/s0034-89102010005000050. Epub 2010 Nov 12. English, Portuguese.
PubMed 21085884Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol. 2013 Feb;69(2):237-44. doi: 10.1007/s00228-012-1321-7. Epub 2012 Jun 17.
PubMed 22706618
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementation of a Hospital Pharmacovigilance Service and Comparison of Algorithms for Adverse Drug Reaction Causality Assessment
- ClinicalTrials.gov ID
- NCT02134587
- Acronym / sponsor ID
- EIPhv / E015/10
- Conditions
- Adverse Drug Reaction
- Keywords
- Health knowledge, attitudes, practices., Adverse drug reaction reporting systems., Pharmacovigilance. Product Surveillance, Postmarketing., Drug-related side effects and adverse reactions.
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 203 participants (actual)
- Lead sponsor
- Universidade Estadual Paulista Júlio de Mesquita FilhoUniversity, hospital or other
- Study start
- Feb 2012
- Primary completion
- Sep 2013 (actual)
- Study completion
- May 2014 (actual)
- First posted
- 9 May 2014 (estimated)
- Results
- Posted 20 Aug 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Spontaneous reports by health professionals generate the signals in pharmacovigilance. However, the passive method has limitations and the most important of them are the underreporting and the poor quality of data, hindering the causality assessment of adverse drug events (ADE). Therefore, the present study aimed to validate an educational intervention (EI) in pharmacovigilance for hospital health professionals, in order to analyze the impact on the knowledge, skill and attitude in ADE reporting.
Investigators proposed a multifaceted EI which will be developed in four meetings with one hour each. The following activities will be carried out: application of a questionnaire to assess the knowledge, skill and attitude before and after EI; lecture; practical class and education material distribution. The answers of questionnaire are going to be analyzed using content analysis technique. The definitions of World Health Organization and the minimum and desired criteria to fill the ADE form, according to the Pan American Health Organization, are going to be considered gold-standard answers. The statistical test of Wilcoxon-Mann Whitney test for paired samples will be applied, in order to assess the impact of educational intervention on behavior of health professionals (ADE reporting).
With the present study, the following hypotheses will be tested:
H0= There is no difference between the numbers of ADE reported (behavior/attitudes) before and after the educational intervention.
H1= The numbers of ADE reported before and after the educational intervention are different.
Detailed description
A quasi-experimental study with health professionals who acted in a general and public hospital of medium complexity with 104 beds will be performed.
Investigators proposed an educational intervention, with the development of lecture and practical class, application of questionnaire before and after EI and the distribution of educational material. Activities will be developed in four meetings of one hour each one.
In the first meeting, questionnaire will be applied, in order to assess knowledge, skills and attitudes in pharmacovigilance prior to EI. The instrument was elaborated based on previous studies. Second meeting will be comprise a lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material, whose content includes the same issues of presentation. In the third meeting, a practical class will be performed to promote a discussion of a fictitious case of adverse drug reaction (ADR), in order to elucidate the correct fill of ADE form. In the fourth meeting, will be repeated the application of questionnaire, in order to assess the impact of EI. With the aim to verify change behavior of health professionals regarding pharmacovigilance activities, the number of ADE reports made prior and after intervention will be compared.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Subjects post educational intervention | Other | Other: Multifaceted educational interventionMultifaceted educational intervention in pharmacovigilance |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- All health professionals (physicians, pharmacists, nurses, auxiliaries of nurses and pharmacists, as well as the multidisciplinary team - social assistants, physiotherapists, audiologists, nutritionists, psychologists, occupational therapists and administrative officers), with employment link at the hospital under study who agree to participate by signing an informed consent form are going to be enrolled.
Key exclusion criteria (1 listed)
- The exclusion criteria meet professionals who will be on sick leave, vacation, those who will not to be registered to carry out the intervention and those who will refuse to answer the questionnaire, despite to having shown interest in participating in the lecture and practical class.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multifaceted educational intervention1. Application of questionnaire of knowledge, attitudes and skills in pharmacovigilance. 2. Lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material 3. Distribution of educational material 4. Practical class to explain the correct fill of adverse drug events form 5. Reapplication of questionnaire of knowledge, attitudes and skills in pharmacovigilance. | Other | Subjects post educational intervention |
Primary outcome
Absolute Number of ADE Reporting (Change Behavior of Health Professionals)
Time frame: 12 months
Investigators are going to verify the numbers of adverse drug events reported by health professionals which was made 12 months before educational intervention. A follow up across 12 months post-educational intervention also will be performed, in order to identify the number of adverse drug events reported by health professionals. Prevalence of ADE in both periods will be estimated and compared, in order to asses the impact of the intervention on change behavior of health professionals.
2 secondary outcomes
Knowledge (Awareness) Regarding Pharmacovigilance
Time frame: Two days
Quality of ADE Reports
Time frame: Two days
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 10448723Figueiras A, Tato F, Fontainas J, Gestal-Otero JJ. Influence of physicians' attitudes on reporting adverse drug events: a case-control study. Med Care. 1999 Aug;37(8):809-14. doi: 10.1097/00005650-199908000-00010.
- Background: PubMed 16119975Herdeiro MT, Figueiras A, Polonia J, Gestal-Otero JJ. Physicians' attitudes and adverse drug reaction reporting : a case-control study in Portugal. Drug Saf. 2005;28(9):825-33. doi: 10.2165/00002018-200528090-00007.
- Background: PubMed 16569082Herdeiro MT, Figueiras A, Polonia J, Gestal-Otero JJ. Influence of pharmacists' attitudes on adverse drug reaction reporting : a case-control study in Portugal. Drug Saf. 2006;29(4):331-40. doi: 10.2165/00002018-200629040-00004.
- Background: PubMed 21830837Gerritsen R, Faddegon H, Dijkers F, van Grootheest K, van Puijenbroek E. Effectiveness of pharmacovigilance training of general practitioners: a retrospective cohort study in the Netherlands comparing two methods. Drug Saf. 2011 Sep 1;34(9):755-62. doi: 10.2165/11592800-000000000-00000.
- Background: PubMed 19132807Pedros C, Vallano A, Cereza G, Mendoza-Aran G, Agusti A, Aguilera C, Danes I, Vidal X, Arnau JM. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Saf. 2009;32(1):77-83. doi: 10.2165/00002018-200932010-00007.
- Background: PubMed 16954488Figueiras A, Herdeiro MT, Polonia J, Gestal-Otero JJ. An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. JAMA. 2006 Sep 6;296(9):1086-93. doi: 10.1001/jama.296.9.1086.
- Background: PubMed 22788235Herdeiro MT, Ribeiro-Vaz I, Ferreira M, Polonia J, Falcao A, Figueiras A. Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Saf. 2012 Aug 1;35(8):655-65. doi: 10.1007/BF03261962.
- Background: PubMed 18366244Herdeiro MT, Polonia J, Gestal-Otero JJ, Figueiras A. Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Saf. 2008;31(4):335-44. doi: 10.2165/00002018-200831040-00007.
- Background: PubMed 21085884Ribeiro-Vaz I, Herdeiro MT, Polonia J, Figueiras A. Strategies to increase the sensitivity of pharmacovigilance in Portugal. Rev Saude Publica. 2011 Feb;45(1):129-35. doi: 10.1590/s0034-89102010005000050. Epub 2010 Nov 12. English, Portuguese.
- Background: PubMed 22706618Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol. 2013 Feb;69(2):237-44. doi: 10.1007/s00228-012-1321-7. Epub 2012 Jun 17.
Related trials for Adverse Drug Reaction
Not yet recruitingPhase 2
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy
Not yet recruiting
Feasibility Study of Huangqi Yangyuan Formula for Capecitabine-Induced Adverse Reactions in Advanced Colorectal Cancer
Advanced Colorectal Cancer, Capecitabine-Related Adverse Reaction
RecruitingPhase 4
Propofol-Ketamine Versus Sevoflurane for Laryngeal Mask Anesthesia in Pediatric Cardiac Catheterization
Propofol, Ketamine
Active, not recruiting
Introducing Electronic Alerts to Reduce Inappropriate Digoxin Prescribing in Older Adults
Drug-Related Side Effects and Adverse Reaction, Digoxin Overdose
RecruitingObservational study
Reduction of Adverse Drug Events and Readmissions
Pharmacogenomic Testing for Medication Management
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Patricia C Mastroianni, PhD study chair
School of Pharmaceutical Sciences of Unesp
Fabiana R Varallo, Master principal investigator
School of Pharmaceutical Sciences of Unesp
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multifaceted educational intervention in people with Adverse Drug Reaction, run by Universidade Estadual Paulista Júlio de Mesquita Filho at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 20 Aug 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Absolute Number of ADE Reporting (Change Behavior of Health Professionals) (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02134587, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2023.